Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot liver cancer recurrence before scans do

NCT ID NCT06157060

Diagnosis Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can predict if liver cancer will come back after surgery. Researchers will follow 255 patients for two years, taking blood samples regularly to see if the test detects recurrence earlier than standard imaging. If it works, this could lead to earlier treatment and better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
circulating tumor DNA (ctDNA) blood test
What this could lead to
If successful, this blood test could help doctors detect liver cancer recurrence months earlier than standard imaging, allowing for timely treatment.
What could go wrong
This is an early-stage study with 255 participants, so results may not apply to all patients. The test may not reliably predict recurrence in every case.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 255 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with hepatocellular carcinoma who can undergo radical surgical resection

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients aged 18-75 years; 2. Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 / stage A/stage B, eligible for radical surgery; 3. ECOG physical status score is 0-1; 4. Child-Pugh score is 5-6 points (Level A); 5. Not received any anti-tumor therapy; 6. Laboratory tests were at normal levels within 7 days before enrollment. Exclusion Criteria: 1. Patient can't provide blood samples for ctDNA testing; 2. Patient with two or more types of tumors at the same time; 3. Non-primary liver lesions; 4. Pregnant or lactating women; 5. Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma; 6. Patient with serious heart disease; 7. Other conditions deemed unsuitable for inclusion by the researcher.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma resectable are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma resectable

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    RECRUITING

    Guangzhou, Guangdong, China

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    RECRUITING

    Guangzhou, Guangdong, China

  • Shunde Hospital of Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital of South China University of Technology

    RECRUITING

    Foshan, Guangdong, China

  • Yuebei People's Hospital

    RECRUITING

    Shaoguan, Guangdong, China

  • Zhujiang Hospital of Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 510220, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.